Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631882 | 0.91 | CYP1A2 (0.58) | CYP1A2GRIA2VCAM1ALDH1A1CYP3A4 | |
| SCHEMBL4811478 | 0.90 | CYP1A2 (0.53) | CYP1A2GRIA2VCAM1ALDH1A1CYP3A4 | |
| SCHEMBL4815319 | 0.90 | CYP1A2 (0.53) | CYP1A2GRIA2VCAM1ALDH1A1CYP3A4 | |
| SCHEMBL26684909 | 0.85 | CYP1A2 (0.53) | CYP1A2GRIA2VCAM1CYP3A4PDK1 | |
| SCHEMBL19180352 | 0.85 | CYP1A2 (0.49) | CYP1A2GRIA2VCAM1ALDH1A1CYP3A4 | |
| SCHEMBL19182411 | 0.85 | CYP1A2 (0.49) | CYP1A2GRIA2VCAM1ALDH1A1CYP3A4 | |
| SCHEMBL26684848 | 0.82 | CYP1A2 (0.53) | CYP1A2GRIA2VCAM1ALDH1A1CYP3A4 | |
| SCHEMBL31570157 | 0.82 | CYP1A2 (0.53) | CYP1A2GRIA2VCAM1ALDH1A1CYP3A4 | |
| SCHEMBL31722848 | 0.81 | PDGFRB (0.60) | CYP1A2GRIA2VCAM1ALDH1A1CYP3A4 | |
| SCHEMBL31726681 | 0.81 | PDGFRB (0.60) | CYP1A2GRIA2VCAM1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083434-A1 | DIVALENT NUCLEOBASE COMPOUNDS AND USES THEREFOR | CARNEGIE MELLON UNIVERSITY (US) | 2016-03-24 | — | — | US | disclosed |
| US-8003624-B2 | Functionally selective ALPHA2C adrenoreceptor agonists | SCHERING CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1945626-B1 | IMIDAZOLE DERIVATIVES AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORP (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7803828-B2 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING-PLOUGH CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| EP-2125784-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008100457-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1945626-A1 | IMIDAZOLE DERIVATIVES AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
| WO-2007024944-A1 | IMIDAZOLE DERIVATIVES AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083434-A1 | DIVALENT NUCLEOBASE COMPOUNDS AND USES THEREFOR | DNTT, POLM, POLL | CYP1A2 4885/4885GRIA2 2449/4885VCAM1 1651/4885 |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | CYP1A2 205/4885GRIA2 217/4885VCAM1 1171/4885 |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | CYP1A2 205/4885GRIA2 217/4885VCAM1 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.